Pharma start-up Cellectar adds to executive team

Madison, Wis. - In appointments that reflects the progress of its lead drug candidate, Cellectar, LLC, a privately-held radiopharmaceutical company, has named Ernest Allen as director of clinical operations and Lisa Ann Trembath as manager of medical affairs.

Cellectar, which designs and develops products to detect, treat, and monitor human cancers, is developing its lead product, CLR1404, toward clinical trials. Preclinical testing has shown the compound is retained in 100 percent of more than 40 malignant tumor types.

Dr. Bill Clarke, president and CEO of Cellectar, which has raised $9 million from angel investors, said Allen and Trembath bring the clinical development skills needed to advance CLR1404 toward clinical trials.

Allen comes to Cellectar from Tapestry Pharmaceuticals, a cancer treatment pharmaceutical company located in Boulder, Colo. He has more than 20 year's experience in senior positions in clinical operations for pharmaceutical companies, including Parke-Davis and Origin Pharmaceuticals, a U.K.-based clinical research organization.

Trembath brings 21 years of experience as a nuclear medicine technologist, having specialized in medical imaging. More recently, she served as senior clinical affairs specialist in the medical affairs division at Bristol-Myers Squibb Medical Imaging. She also has coordinated clinical trials research at the Medical College of Wisconsin. Related stories

• Breaking down Wisconsin's angel capital numbers

• Bill Shepard: UW biotech program launches graduates into evolving industry (part 2)

• WorkWise Helps Manufacturers Squeeze Bottom Line